Quarterly report pursuant to Section 13 or 15(d)

Stock Options

v3.24.3
Stock Options
9 Months Ended
Sep. 30, 2024
Stock Options [Abstract]  
STOCK OPTIONS

NOTE 7 – STOCK OPTIONS

 

Stock Options Issued, Vested and Cancelled

 

During the three months ended September 30, 2024, the Company did not issue any stock options. During the three months ended September 30, 2024, 4,771 stock options subject to time-based milestone vesting conditions, vested.

 

During the nine months ended September 30, 2024, the Company granted stock options under the 2023 Plan to employees, to purchase an aggregate of 104,433 shares of Common Stock with a strike price equal to $8.13 per share and a term of ten years. Of the stock options granted, stock options to purchase an aggregate of 37,433 shares of Common Stock were fully vested at issuance and the remaining stock options are subject to time-based vesting over a term ranging between one to three years. These stock options had a total fair value of approximately $849,000, as calculated using the Black-Scholes pricing model with the following assumptions: volatility of 88.41%, discount rate of 4.20%, expected term of 6.5 years, and an exercise price of $8.13. 

 

During the nine months ended September 30, 2024, stock options to purchase an aggregate of 52,309 shares of Common Stock, subject to time-based milestone vesting conditions, vested.

 

During the nine months ended September 30, 2024, stock options to purchase an aggregate of 17,649 shares of Common Stock were cancelled in connection with the reduction in workforce related to the closure of our research laboratory.

 

Stock-Based Compensation

 

For the three months ended September 30, 2024 and 2023, total stock-based compensation expense related to the Company’s stock options was approximately $121,000 and $102,000, respectively. For the three months ended September 30, 2024, the Company recognized approximately $107,000 of stock-based compensation related to its stock options within general and administrative expense, and approximately $14,000 within research and development expense on the condensed consolidated statements of operations and comprehensive loss. For the three months ended September 30, 2023, all stock-based compensation expense was recorded within general and administrative expense on the condensed consolidated statements of operations and comprehensive loss.

 

For the nine months ended September 30, 2024 and 2023, total stock-based compensation expense related to the Company’s stock options was approximately $553,000 and approximately $451,000, respectively. For the nine months ended September 30, 2024, the Company recognized approximately $398,000 of stock-based compensation related to its options within general and administrative expense, and approximately $155,000 within research and development expense. For the nine months ended September 30, 2023, all stock-based compensation expense was recorded within general and administrative expense.

 

The following table summarizes the activity related to the Company’s stock options for the nine months ended September 30, 2024:

 

    Number of Options     Weighted average
exercise price
per share
    Weighted average
remaining
contractual term
(years)
    Aggregate
intrinsic value
(in thousands)
 
Outstanding, January 1, 2024     99,000     $ 32.38       8.55     $
        -
 
Granted     104,433       8.13       8.63      
-
 
Expired/Cancelled     (17,649 )     9.35       -      
-
 
Exercised    
-
     
-
      -      
-
 
Outstanding, September 30, 2024     185,784     $ 20.21       9.13      
-
 
                                 
Exercisable, September 30, 2024     95,514     $ 30.27       8.24     $
-
 

 

As of September 30, 2024, the remaining unamortized stock-based compensation expense related to the stock options was approximately $476,000 with remaining 28 months of amortization.